Key points from article :
Discovered a novel virulence mechanism by which bacteria suppress the immune response of their infected host.
Immunethep’s technology targets an extracellular protein conserved across different pathogenic bacteria.
By neutralizing the protein, Immunethep states its technology can protect patients against infection.
Raised €700,000 in seed funding in 2015.
Series A funding to enter a Phase I trial for its first product, Paragon Novel Vaccine.
PNV1 will be the first vaccine that can protect patients against multibacterial infections, including different variants, or serotypes, of the same bacterial species.
The fact that PNV1 would be the first vaccine of this kind highlights the difficulty in developing this type of treatment. I am interested to see whether PNV1 successfully advances through the pipeline.
